{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:21:36Z","timestamp":1763529696240,"version":"3.45.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The heterogeneous prognosis of bladder urothelial carcinoma (BLCA) remains a significant clinical challenge. A multi-factor prognostic model is essential for BLCA, as it not only assesses tumor progression and elucidates underlying molecular mechanisms but also paves the way for timely treatment adjustments and improved clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using R software, we performed immunophenotyping on multiple BLCA cohorts from the GEO database to identify shared immune signatures. Simultaneously, we identified BLCA prognosis-associated genes by analyzing TCGA data. Prognostic genes were further refined via LASSO regression, allowing BLCA patients to be stratified into high- and low-risk groups based on their expression patterns. Quantitative PCR (qPCR) was used to validate gene expression in tumor and matched normal tissues. Finally, we integrated clinical data to construct a prognostic model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The GSE31684 and GSE48276 cohorts were divided into high immunity (Immunity_H) and low immunity (Immunity_L) groups, and there were significant microenvironment differences between the Immunity_H and Immunity_L of the two cohorts, and there were many common differentially expressed genes (DEGs) between different immune subtypes of the two cohorts, which were mainly involved in immune-related biological processes. In addition, patients in the high-risk BLCA group exhibited significantly worse prognosis than those in the low-risk group. qPCR analysis confirmed that the expression levels of the risk-stratification genes were significantly different between BLCA tumors and matched adjacent normal tissues. The integrated analysis of tumor mutation burden (TMB) and our risk stratification revealed that patients with low-risk scores and high TMB exhibited the most favorable prognosis. Furthermore, the risk score was validated as an independent prognostic factor through both univariate and multivariate Cox regression analyses. Consequently, we constructed a nomogram that incorporates these findings to assist clinicians in prognostic assessment for BLCA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Given that the tumor microenvironment significantly influences BLCA prognosis, our finding that risk stratification serves as an independent prognostic indicator underscores the clinical relevance of our model. This stratification strategy has the potential to improve prognostic assessment and inform personalized treatment planning for BLCA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2025.1702311","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:39Z","timestamp":1763529519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressively exploring and assessing the prognosis of bladder urothelial cancer based on the microenvironment through the integration of multiple databases"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiong","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changshi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cmet.2018.09.012","article-title":"Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy","volume":"29","author":"Bertero","year":"2019","journal-title":"Cell metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"102141","DOI":"10.1016\/j.xcrm.2025.102141","article-title":"Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade","volume":"6","author":"Blanchard","year":"2025","journal-title":"Cell Rep. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.euo.2023.02.011","article-title":"Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities","volume":"6","author":"Caramelo","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: an update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.urolonc.2018.11.015","article-title":"Molecular tumor heterogeneity in muscle invasive bladder cancer: biomarkers, subtypes, and implications for therapy","volume":"40","author":"da Costa","year":"2018","journal-title":"Urol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2024.01.023","article-title":"Prognostic impact and spatial interplay of immune cells in urothelial cancer","volume":"86","author":"Debatin","year":"2024","journal-title":"Eur. Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105177","DOI":"10.1016\/j.ebiom.2024.105177","article-title":"Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4\/6 inhibitor therapy in oesophageal squamous cell carcinoma","volume":"105","author":"Gao","year":"2024","journal-title":"EBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"629909","DOI":"10.3389\/fonc.2020.629909","article-title":"Identification of an immune gene-associated prognostic signature and its association with a poor prognosis in gastric cancer patients","volume":"10","author":"Guan","year":"2020","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinforma."},{"key":"B15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12916-021-02163-6","article-title":"5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer","volume":"19","author":"Hu","year":"","journal-title":"BMC Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Hu","year":"","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e33275","DOI":"10.1097\/MD.0000000000033275","article-title":"Prognostic factors and nomogram for the overall survival of bladder cancer bone metastasis: a SEER-based study","volume":"102","author":"Huang","year":"2023","journal-title":"Med. Baltim."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-021-01479-4","article-title":"On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1097\/JS9.0000000000001516","article-title":"Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jad.2023.11.086","article-title":"Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: a population-based retrospective study","volume":"347","author":"Liu","year":"2024","journal-title":"J. Affect Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"B24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41590-022-01161-x","article-title":"The transcription factor LRF promotes integrin \u03b27 expression by and gut homing of CD8\u03b1\u03b1+ intraepithelial lymphocyte precursors","volume":"23","author":"Nie","year":"2022","journal-title":"Nat. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2021","journal-title":"ESMO Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-tumor heterogeneity from a cancer stem cell perspective","volume":"16","author":"Prasetyanti","year":"2017","journal-title":"Mol. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","article-title":"Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: a nonrandomized controlled trial","volume":"9","author":"Provencio","year":"2023","journal-title":"JAMA Oncol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.09.003","article-title":"Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses","author":"Ren","year":"2025","journal-title":"Cancer cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"599723","DOI":"10.3389\/fonc.2020.599723","article-title":"Editorial: metabolic plasticity of cancer","volume":"10","author":"Rodriguez-Enriquez","year":"2020","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3389\/fimmu.2019.01713","article-title":"Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis","volume":"10","author":"Schulz","year":"2019","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.3324\/haematol.2023.283471","article-title":"The glutamate\/aspartate transporter EAAT1 is crucial for T-cell acute lymphoblastic leukemia proliferation and survival","volume":"109","author":"Stanulovic","year":"2024","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/biomedicines10092109","article-title":"High tumor mutation burden is associated with poor clinical outcome in EGFR-mutated lung adenocarcinomas treated with targeted therapy","volume":"10","author":"Sung","year":"2022","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13287-020-01973-4","article-title":"Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling","volume":"11","author":"Tang","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1015308","DOI":"10.3389\/fonc.2022.1015308","article-title":"High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur. Urol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat. Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6149369","DOI":"10.1155\/2022\/6149369","article-title":"Identification of survival risk and immune-related characteristics of kidney renal clear cell carcinoma","volume":"2022","author":"Wu","year":"2022","journal-title":"J. Immunol. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-024-01945-9","article-title":"Multi-cohort validation of ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e003416","DOI":"10.1136\/jitc-2021-003416","article-title":"Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer","volume":"10","author":"Xu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.apsb.2021.07.011","article-title":"TGR5 deficiency activates antitumor immunity in non-small cell lung cancer via restraining M2 macrophage polarization","volume":"12","author":"Zhao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B42","doi-asserted-by":"publisher","first-page":"698856","DOI":"10.3389\/fonc.2021.698856","article-title":"A novel ferroptosis-related gene model for overall survival predictions of bladder urothelial carcinoma patients","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/biom12111670","article-title":"Identification of immune-related subtypes and construction of a novel prognostic model for bladder urothelial cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer. Biomol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"188926","DOI":"10.1016\/j.bbcan.2023.188926","article-title":"Off the fog to find the optimal choice: research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer","volume":"1878","author":"Zhao","year":"2023","journal-title":"Biochimica biophysica acta Rev. cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2020.00102","article-title":"Traditional classification and novel subtyping systems for bladder cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Front. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7457","DOI":"10.1038\/s41467-025-62399-1","article-title":"COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1702311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:40Z","timestamp":1763529520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1702311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":46,"alternative-id":["10.3389\/fmolb.2025.1702311"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1702311","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1702311"}}